Fibrolex Technologies' scientific premise for treatment of liver fibrosis is based on the discovery of a critical regulatory mechanism for fibrosis progression: binding of protein LARP6 to the mRNAs encoding for type I collagen. This discovery was originally made by the Fibrolex Technologies founder and allows the therapeutic approach to directly combat the pathogenesis of fibrosis: excessive type I collagen biosynthesis.

A novel proprietary inhibitor of LARP6 binding and collagen biosynthesis has been discovered by the FibrolexTechnologies team. FibrolexTechnologies is developing this inhibitor as the monodisperse polymer, with high efficacy, chemically stability and low cytotoxicity. The large surface area of the inhibitor is the basis for its potency and permits coupling to a ligand for targeted delivery into cells responsible for liver fibrosis.

Our strategic focus is on hepatic stellate cells, as the cells producing type I collagen in liver fibrosis. By coupling the inhibitor to the ligand which can specifically recognize active hepatic stellate cells, FibrolexTechnologies is creating a self-delivering fibrosis therapeutic. Reducing the side effects by targeted delivery is of utmost importance, because liver fibrosis is a chronic disease requiring life-long treatment.